Zenas BioPharma (ZBIO) CEO Moulder bought 70,000 shares for $718K at an average $10.26
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Leon O Moulder Jr (Chief Executive Officer at Zenas BioPharma Inc., ZBIO) reported that they bought 70,000 shares for $718K at an average $10.26 between Dec 3, 2024 and Dec 4, 2024. After these transactions the filing shows 241,155 shares held directly.
- Reporting person
- Moulder Leon O Jr
- Role
- Chief Executive Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Dec 3, 2024 | Open-market purchase (P) | Common Stock1 | +25,000 | $10.76 | $269K | 196,155 direct |
| Dec 4, 2024 | Open-market purchase (P) | Common Stock2 | +45,000 | $9.98 | $449K | 241,155 direct |
Holdings before and after
- Common Stock: 171,155 to 241,155 direct
Other positions listed
- Common Stock: 1,672,039 indirect, See Footnote
Footnotes from the filing
- 1. The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $10.73 to $10.88, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- 3. Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ( Tellus ) and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Transaction codes in this filing
- Open-market purchase:
- Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
FAQ
What did Moulder report in this ZBIO Form 4?
Leon O Moulder Jr (Chief Executive Officer at Zenas BioPharma Inc., ZBIO) reported that they bought 70,000 shares for $718K at an average $10.26 between Dec 3, 2024 and Dec 4, 2024. After these transactions the filing shows 241,155 shares held directly.
How many ZBIO shares does Moulder hold after this filing?
The filing shows 241,155 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code P mean on an SEC Form 4?
Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
Historical context for ZBIO
Earlier insider filings at ZBIO
- Nov 20, 2024Chief Executive Officer Moulder Leon O Jr bought $148,925 worth of shares (10,000 units at $14.89), increasing direct ownership by 6% to 171,155 units (SEC Form 4)
- Sep 20, 2024Chief Executive Officer Moulder Leon O Jr bought $360,820 worth of shares (20,000 units at $18.04) (SEC Form 4)
- Sep 18, 2024Amendment: Director Fairmount Funds Management Llc converted options into 1,304,891 shares and bought $5,100,000 worth of shares (300,000 units at $17.00) (SEC Form 4)
- Sep 18, 2024Amendment: Chief Executive Officer Moulder Leon O Jr converted options into 693,175 shares, increasing direct ownership by 3,465% to 161,155 units (SEC Form 4)
- Sep 17, 2024Director Lu Hongbo bought $999,991 worth of shares (58,823 units at $17.00) (SEC Form 4)
Keep researching ZBIO
- ZBIO insider tradesEvery buy and sale reported by Zenas BioPharma Inc. officers, directors and large holders.
- What is Insider buying?Purchases of a company's stock by its officers, directors or 10% holders, reported to the SEC on Form 4 and watched as a signal of insider confidence.
- How to track insider buyingInsider buying is tracked through SEC Form 4 code P filings. Learn how to find open-market purchases, spot cluster buys and judge which insider trades carry real signal.
- Insider trading trackerThe latest insider buys and sales across every stock.
- ZBIO earnings historyPast Zenas BioPharma Inc. earnings releases, newest first.
- ZBIO financial statementsRevenue, profit, cash flow and balance sheet from Zenas BioPharma Inc.'s SEC filings.
Quantisnow market dataNASDAQ
ZBIO
Zenas BioPharma Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Get push alerts for ZBIO
Full ZBIO profile on Quantisnow Follow ZBIO and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time